AstraZeneca on Thursday said it will pay up to $6.9 billion to work with Daiichi Sankyo on a treatment for breast cancer. Compared to the risk of an acquisition, it’s a relatively painless way of expanding in a hot area, says Unmack1:
AstraZeneca said on March 28 that it would pay up to $6.9 billion to Daiichi Sankyo to develop and sell a cancer drug developed by the Japanese company.
The drug, called Trastuzumab Deruxtecan, allows chemotherapy products to target specific cancer tumours. It is being developed for certain breast cancer patients, and may also be used for lung and colorectal cancers. AstraZeneca will pay Daiichi Sankyo $1.35 billion upfront, with an additional $3.8 billion contingent on the drug clearing regulatory milestones, and $1.75 billion dependent on future sales.
AstraZeneca also said it will raise $3.5 billion through a placing of new shares, of which more than half will be used to fund the transaction and the product’s future development. AstraZeneca shares were down 3.9 percent at 62.45 pounds by 0930 GMT on March 29. Daiichi Sankyo shares closed up 16 percent at 5,100 yen.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
AstraZeneca inks $6.9 billion cancer drug pact with Japanese pharma firm Daiichi SankyoAstraZeneca and Japan's Daiichi Sankyo signed a potential multibillion-dollar deal to develop and sell Daiichi's cancer drug trastuzumab deruxtecan.
Consulte Mais informação »
AstraZeneca Strikes $6.9 Billion Cancer Deal With Japanese DrugmakerAstraZeneca has agreed to pay Japan’s Daiichi Sankyo up to $6.9 billion for part of the rights to a promising next-generation cancer treatment, as the Anglo-Swedish pharmaceutical group continues to strengthen its oncology drug pipeline.
Consulte Mais informação »
AstraZeneca in cancer drug deal that could pay Daiichi Sankyo up to $6.9 billionAstraZeneca Plc and Daiichi Sankyo Co Ltd signed a deal to develop and sell Daii...
Consulte Mais informação »
AstraZeneca could pay Daiichi Sankyo up to $6.9 billion in cancer drug dealAstraZeneca Plc and Daiichi Sankyo Co Ltd signed a deal to develop and sell Daii...
Consulte Mais informação »
EU approves AstraZeneca's drug for adjunct use in Type-1 diabetesBritish drugmaker AstraZeneca Plc said on Monday the European Commission approve...
Consulte Mais informação »
Fiat Chrysler might gain from M&A waiting gameThe carmaker is in demand. Already the subject of interest from Peugeot, it could also face a bid from a merged Renault-Nissan, the FT says. Such a deal would be tricky and take time. But patience could give the Agnelli clan better options to solve FCA’s tech and Asian headaches.
Consulte Mais informação »
Holding: Time to put M&A cash cow out to pastureSo-called appraisal cases have rewarded shareholders and deterred dodgy deals. But judges’ reluctance to set share prices, an expert-witness scandal and other trends have made them less lucrative. The HP-Aruba merger gives Delaware’s top court a chance to end the tactic.
Consulte Mais informação »
ING offers savvy alternative to cross-border M&AThe Dutch bank wants to add 1 million profitable customers per year through 2022. Using a single technology platform and fewer branches helps boss Ralph Hamers grow efficiently, without resorting to risky acquisitions. Investors aren’t giving ING’s model enough credit.
Consulte Mais informação »
Global M&A slides in first quarter as Brexit weighs on EuropeGlobal mergers and acquisitions (M&A) sank 17 percent in the first quarter of 20...
Consulte Mais informação »
China’s strong-arm approach to drug addiction does not workChina is tough on drugs. Many traffickers are among the thousands of people executed annually
Consulte Mais informação »